▎WuXiEdited by Kant Content Team

Johnson & Johnson recently announced the latest findings from the Phase 3 clinical trial CARTITUDE-4. The results showed that, in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1 to 3 prior treatment regimens (including proteasome inhibitors) and were lenalidomide-resistant,A single infusion of the CAR-T cell therapy Carvykit (cilta-cel), co-developed with Legend Biotech, significantly improved the minimal residual disease (MRD) negativity rate in patients compared to the standard treatment regimen.MRD is an important prognostic indicator for extending the survival period of patients with multiple myeloma. MRD negativity means that no cancer cells can be detected in the blood using sensitive detection methods.

CARTITUDE-4 is a Phase 3 clinical trial evaluating cilta-cel versus standard therapy in RRMM patients who have received at least one prior treatment.At a median follow-up of 34 months, the MRD negativity rate in evaluable patients was more than double in the cilta-cel treatment group compared to the standard-of-care group (89% vs. 38%; p<0.0001).At 30 months post-treatment, the proportion of evaluable patients in the cilta-cel treatment group who sustained (for 12 months or longer) MRD-negative complete response or better was five times that of the standard treatment group (52% vs. 10%; p<0.0001).

Cilta-cel is a CAR-T cell immunotherapy targeting B-cell maturation antigen (BCMA)., BCMA is primarily expressed on the surface of malignant multiple myeloma B cells and plasma cells. The chimeric antigen receptor protein of Cilta-cel contains two binding domains targeting BCMA, designed to bind with high affinity to human BCMA. After binding to BCMA-expressing cells, the chimeric antigen receptor promotes T-cell activation, proliferation, and clearance of target cells. Cilta-cel was initially developed by Legend Biotech, and in December 2017, Janssen, a subsidiary of Johnson & Johnson, entered into an exclusive global licensing and collaboration agreement with Legend Biotech to co-develop and commercialize cilta-cel.

[1] CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) demonstrated significantly higher rates of minimal residual disease negativity compared to standard therapies in the CARTITUDE-4 study. Retrieved December 11, 2024, from https://www.globenewswire.com/news-release/2024/12/10/2994233/0/en/CARVYKTI-ciltacabtagene-autoleucel-cilta-cel-demonstrated-significantly-higher-rates-of-minimal-residual-disease-negativity-compared-to-standard-therapies-in-the-CARTITUDE-4-study.html

Disclaimer:WuXi AppTec Content Team Focuses on Introducing Global Biomedical and Health Research Progress.This article is for informational exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned in the article.This article is not a recommendation for treatment options.For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.